oral semaglutide obesity Wegovy approved for management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) ECO 2026 - Gastrointestinal Tolerability
Pay in 4 interest-free payments of $6.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 18 - Nov 23


01185-6/asset/2164201a-96aa-45fd-b531-5fbac7f670fe/main.assets/gr2.jpg)























